NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SNY

Sanofi ADR

Jun 30 • 04:00PM ET

48.31

Dollar change +0.46
Percentage change 0.96	%

Healthcare • Drug Manufacturers - General • France • NASD

Peers: NVS PFE MRK GSK BMY LLY AZN JNJ ABBV AMGN

| Held by: PVAL FVD PPH PID AVDE APIE QQQJ BASV BUSA ONEQ

Scroll to Statements

Index	-	P/E	20.18	EPS (ttm)	2.39	Insider Own	0.02%	Shs Outstand	2.61B	Perf Week	0.27%
Market Cap	117.71B	Forward P/E	9.60	EPS next Y	5.03	Insider Trans	0.00%	Shs Float	2.44B	Perf Month	-7.72%
Enterprise Value	128.79B	PEG	1.53	EPS next Q	0.94	Inst Own	10.73%	Short Float	0.18%	Perf Quarter	-13.45%
Income	6.02B	P/S	2.65	EPS this Y	24.34%	Inst Trans	-1.11%	Short Ratio	1.66	Perf Half Y	0.04%
Sales	44.44B	P/B	1.51	EPS next Y	9.04%	ROA	4.29%	Short Interest	4.47M	Perf YTD	0.17%
Book/sh	32.01	P/C	15.04	EPS next 5Y	13.21%	ROE	7.34%	52W High	60.12 -19.64%	Perf Year	-0.04%
Cash/sh	3.21	P/FCF	14.80	EPS past 3/5Y	-6.46% 13.05%	ROIC	6.39%	52W Low	45.80 5.48%	Perf 3Y	-4.18%
Dividend Est.	2.36 (4.89%)	EV/EBITDA	9.06	Sales past 3/5Y	-0.15% 1.91%	Gross Margin	63.49%	Volatility	1.20% 1.37%	Perf 5Y	-7.44%
Dividend TTM	2.21 (4.58%)	EV/Sales	2.90	EPS Y/Y TTM	2.96%	Oper. Margin	23.14%	ATR (14)	0.90	Perf 10Y	-4.79%
Dividend Ex-Date	May 09, 2025	Quick Ratio	0.73	Sales Y/Y TTM	-4.57%	Profit Margin	13.54%	RSI (14)	42.41	Recom	1.68
Dividend Gr. 3/5Y	8.29% 6.46%	Current Ratio	1.08	EPS Q/Q	-	SMA20	-1.41%	Beta	0.47	Target Price	65.59
Payout	66.53%	Debt/Eq	0.23	Sales Q/Q	-	SMA50	-5.16%	Rel Volume	0.63	Prev Close	47.85
Employees	84587	LT Debt/Eq	0.17	Earnings	Apr 24 BMO	SMA200	-7.74%	Avg Volume	2.68M	Price	48.31
IPO	Jul 01, 2002	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.11% 3.35%	Trades		Volume	1,702,452	Change	0.96%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$65
Mar-21-25	Initiated	Goldman	Neutral	$65
Jan-30-25	Upgrade	Deutsche Bank	Sell → Hold
Jul-26-24	Reiterated	Argus	Buy	$55 → $60
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$55
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight

Show Previous Ratings

Today 11:00AM	Hedge Fund Strategy Built on Catastrophes Taps Hot New Trend (Bloomberg)
01:30AM	Press release: Availability of the Q2 2025 Aide mémoire (GlobeNewswire)
01:00AM	Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy (GlobeNewswire)
Jun-27-25 10:19AM	Kymeras partnerships with Sanofi and Gilead drive value (Investing.com)
Jun-26-25 02:28PM	The Anti-Vax Movement Solidifies Control of the CDCs Vaccine Committee (Barrons.com)
10:45AM	Loading…
10:45AM	Kymera weakness a buying opportunity, says Stifel (TipRanks)
09:06AM	Morning Movers: General Mills dips following fourth quarter report (TipRanks)
08:40AM	KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update (Zacks)
08:00AM	Sanofi awards Healthy Futures Solution Fund grants to advance community-led solutions, expand equitable access to care across Massachusetts (PR Newswire)
Jun-25-25 10:02AM	Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag (Zacks)
01:00AM	Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation (GlobeNewswire)
Jun-24-25 09:56AM	Sanofi Trades Below 50 & 200-Day Moving Averages: Time to Buy the Dip? (Zacks)
Jun-23-25 12:34PM	SNY Gets CHMP Nod for Expanded Use of Sarclisa in Multiple Myeloma (Zacks)
01:00AM	Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma (GlobeNewswire)
Jun-20-25 09:46AM	Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid (Zacks)
05:11AM	Loading…
05:11AM	DoH Abu Dhabi and Sanofi link for vaccine development (Pharmaceutical Technology)
01:00AM	Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid (GlobeNewswire)
Jun-19-25 10:23AM	What is the Intent Behind Eli Lilly's Recent M&A Deals Spree? (Zacks)
Jun-18-25 10:00AM	Trump administration weighs crackdown on pharma ads, Bloomberg says (TipRanks)
Jun-17-25 02:39PM	Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards? (Zacks)
12:12PM	Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly (Zacks)
07:40AM	Press release: Sanofi successfully prices 1.5 billion bond issue (GlobeNewswire)
Jun-16-25 09:06AM	5 Large Drug Stocks That Are Poised to Ride on Sector Recovery (Zacks)
Jun-15-25 11:22AM	Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study (GlobeNewswire)
11:21AM	Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial (GlobeNewswire)
05:47AM	Berenberg Bank Remains a Buy on Sanofi (SNY), Sets a 118 Price Target (Insider Monkey)
05:38AM	Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis (Insider Monkey)
Jun-13-25 12:45PM	Senators to propose ban on drug ads to consumers, WSJ reports (TipRanks)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
08:15AM	Novavax's COVID-Flu Combo Shot Shows Strong Immune Response (Zacks)
10:20AM	Loading…
Jun-11-25 10:20AM	Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel (TipRanks)
Jun-10-25 10:50AM	Merck Secures FDA Nod for New RSV Antibody Enflonsia in Infants (Zacks)
08:18AM	Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. (Barrons.com)
Jun-09-25 05:10PM	Sanofi: Information concerning the total number of voting rights and shares - May 2025 (GlobeNewswire)
05:01PM	S&P 500 Gains and Losses Today: Edison International Stock Falls as Analysts Cites Liability Risk (Investopedia)
12:03PM	Merck antibody drug for RSV approved by FDA (BioPharma Dive)
11:00AM	Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season (Benzinga)
10:30AM	Regeneron and Sanofis dupilumab shows promise in AD trial (Clinical Trials Arena)
10:00AM	Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care (PR Newswire)
08:44AM	Acquisitions, Licensing Deals Take Centerstage in Pharma/Biotech Space (Zacks)
01:00AM	Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season (GlobeNewswire)
Jun-06-25 04:16PM	Challenges pharma companies face in push into US manufacturing (Yahoo Finance Video)
02:10PM	Sanofi (SNY) Stock Down 5% Despite AERIFY-1 Success (Insider Monkey)
Jun-05-25 08:45AM	REGN Strengthens Obesity Pipeline: Will the Move Revive the Stock? (Zacks)
04:00AM	Press release: Sanofi Launches 2025 Global Employee Stock Purchase Plan (GlobeNewswire)
02:00AM	Global Markets Are On a Tear. These Stocks in Europe and Japan Are Still Bargains. (Barrons.com)
Jun-04-25 12:06PM	MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
08:40AM	Sanofi announces new data from two clinical studies on Sarclisa (TipRanks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
08:26AM	Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector (GlobeNewswire)
01:00AM	Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease (GlobeNewswire)
Jun-02-25 06:40PM	Analyst Report: Sanofi (Morningstar Research)
01:39PM	Sanofi Just Spent $9.5 Billion on a Rare Disease You've Never Heard Of (GuruFocus.com)
12:09PM	Top Stock Movers Now: Ford, Cleveland-Cliffs, Moderna, and More (Investopedia)
11:58AM	Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines (Zacks)
11:45AM	M&A is 'lifeblood' of biopharma: Analyst on Sanofi-Blueprint deal (Yahoo Finance Video)
11:43AM	Sanofi to acquire Blueprint Medicines, Boeing upgrade (Yahoo Finance Video)
10:54AM	Sanofi to expand immunology offerings with Blueprint Medicines (Pharmaceutical Technology)
08:54AM	Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover (Investopedia)
08:42AM	Stocks to Watch Monday: Alphabet, Tesla, UnitedHealth, Steel Dynamics (The Wall Street Journal)
08:12AM	Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout (Benzinga)
07:38AM	5 Things to Know Before the Stock Market Opens (Investopedia)
06:50AM	Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. (Barrons.com)
06:41AM	Sanofi and Regeneron report results from two Phase III trials of COPD treatment (Pharmaceutical Technology)
05:11AM	Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline (The Wall Street Journal)
01:25AM	Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology (PR Newswire)
01:24AM	Sanofi to buy US biopharma group Blueprint for up to $9.5 billion (Reuters)
01:22AM	Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion (The Wall Street Journal)
01:00AM	Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology (GlobeNewswire)
May-30-25 06:23PM	Analyst Report: Sanofi (Morningstar Research) -5.69%
04:23PM	Regeneron stock sinks over trial data for smoker's lungs drug (Yahoo Finance Video)
11:59AM	Top Stock Movers Now: Regeneron, Ulta Beauty, Cooper, and More (Investopedia)
10:31AM	COPD Drug Developed by Regeneron, Sanofi Fails Key Test (Investopedia)
10:19AM	Regeneron, SNY Report Mixed Results From Late-Stage COPD Studies (Zacks)
10:11AM	Regeneron Stock Plunges. Why a Drug Trial Missed the Mark. (Barrons.com)
10:00AM	Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates (Zacks)
08:59AM	Regeneron Pharmaceuticals Crashes 18% On A Surprise Sanofi-Tied Failure (Investor's Business Daily)
08:30AM	Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data (Benzinga)
08:08AM	Stocks to Watch Friday: Dell, Costco, Ulta, Regeneron (The Wall Street Journal)
06:37AM	Regeneron shares slide on mixed trial data for smoker's lung drug (Reuters)
06:34AM	Sanofi, Regeneron Respiratory Drug Delivers Mixed Results in Key Trials (The Wall Street Journal)
04:25AM	Sanofi, Regeneron shares nosedive after mixed Itepekimab results (Investing.com)
03:19AM	Sanofi, Regenerons Itepekimab Delivers Mixed Results in Late-Stage Trials (The Wall Street Journal)
01:00AM	Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies (GlobeNewswire)
01:00AM	Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials (GlobeNewswire)
May-29-25 08:30AM	Press Release: Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs (GlobeNewswire)
03:46AM	Sanofi: New Anthem from Girl Band Raises Awareness of Type 1 Diabetes After Research Highlights Silent Struggle (PR Newswire)
May-27-25 11:19AM	TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock? (Zacks)
10:00AM	RXRX vs. SDGR: Which AI-Powered Drug Discovery Stock Has More Upside? (Zacks)
01:00AM	Press Release: Sanofi completes acquisition of DR-0201 (GlobeNewswire)
May-23-25 08:16AM	Pharma Stock Roundup: NVO CEO Resigns, SNY to Buy VIGL & More (Zacks)
07:45AM	Analysts Think These Stocks Could More Than Double in Value (MarketBeat)
06:19AM	FDA Approves GSK's Nucala for Expanded Use in COPD (Zacks)
May-22-25 07:50PM	Vigil Neuroscience to be acquired by Sanofi for $8.00 per share (TipRanks)
05:30PM	Sanofi opens new, $130 million NJ offices in Morristown, showcasing innovative, modern design and strengthening US presence (PR Newswire)
12:20PM	Sanofi buys Vigil Neuroscience for $470m in Alzheimers push (Pharmaceutical Technology)
11:40AM	Vigil Neuroscience Stock Triples as Drugmaker Agrees to Acquisition by Sanofi (Investopedia)
10:48AM	MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot (Zacks)
10:14AM	Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout (Zacks)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNY

Sanofi ADR

Upgrade your FINVIZ experience